[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dermatologic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dermatologic-disease":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,75,106,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637567","phase-2-a-phase-2b-study-of-the-effects-of-camoteskimab-in-adults-with-moderate-to-severe-atopic-dermatitis-100637567",false,"NCT07599813","A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Age 18-65 inclusive, at the time of signing the informed consent.\n2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.\n3. Participants with moderate-to-severe AD defined by:\n\n   1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.\n   2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.\n   3. EASI score of ≥ 16 at Screening and at Baseline.\n   4. Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed.\n4. Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.\n5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n6. Participant provides signed informed consent\n\nExclusion Criteria:\n\n1. History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.\n2. Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.\n3. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.\n4. Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.\n5. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.\n6. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.\n7. Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator.\n8. Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit.\n9. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test.\n10. Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+).\n11. Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled.\n12. Evidence of active or latent tuberculosis.\n13. Receipt of live or attenuated live vaccine within 6 weeks prior to screening.\n14. Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.\n15. Participant is known to have immune deficiency or is immunocompromised\n16. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of:\n\n    * Completely resected basal cell or squamous cell carcinoma of the skin.\n    * Carcinoma in situ of the cervix.\n17. Has had previous exposure to anti-IL-18 therapy.\n18. Known allergy\u002Fsensitivity to any component of IMP.\n19. History of use of any of these medications as follows:\n\n    1. Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline.\n    2. Systemic JAKi within 4 weeks prior to Baseline.\n    3. Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths.\n    4. Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral\u002Finjectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.\n    5. Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening.\n    6. Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening.\n    7. UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study.\n    8. PUVA treatment within 4 weeks prior to Baseline\n    9. Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline\n    10. Topical products containing urea within 1 week prior to Baseline\n    11. Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline\n    12. Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline.\n20. Female participant who is pregnant or breastfeeding or trying to conceive.\n21. Participant considered unlikely to adhere to treatment and\u002For follow the protocol in the opinion of the Investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.",[27,28,29,30,31,32,33,34],"Atopic Dermatitis","Atopic","Dermatitis","Dermatitis, Atopic","Dermatologic Disease","Eczema","Eczema Atopic Dermatitis","Eczema, Atopic","RECRUITING","2026-05-29",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":39},"2026-05-28",{"date":43,"type":21},"2028-04-30",{"name":45,"class":46},"Apollo Therapeutics Ltd","INDUSTRY",85,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100532843","vitiligo-registry-for-adults-and-children-in-the-uk-100532843","NCT06218082","Vitiligo Registry for Adults and Children in the UK","Vitiligo Registry for Adults and Children in the UK (VIRTUAL-UK)","VIRTUAL-UK","Inclusion Criteria:\n\n1. Paediatric and adult patients with vitiligo under management in secondary care.\n2. Written informed consent for study participation obtained from the patient or parents \u002F legal guardian, with assent as appropriate by the patient, depending on the level of understanding.\n3. Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team\n4. Clinical diagnosis of vitiligo made by a dermatologist\n5. Willingness to comply with all study requirements.\n6. Competent use of English language, according to patient's age (capable of understanding patient questionnaires).\n\nExclusion Criteria:\n\n1. Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n2. Patients with vitiligo\u002Ftheir parents or guardians, who do not provide consent for participation.",{"count":57,"type":21},30,"1 Year","OBSERVATIONAL","Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.\n\nCurrently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.",[31,62],"Vitiligo","NOT_YET_RECRUITING","2026-04-08",{"date":66,"type":39},"2026-04-09",{"date":68,"type":21},"2026-05-15",{"date":70,"type":21},"2030-02",{"name":72,"class":73},"The Royal Wolverhampton Hospitals NHS Trust","OTHER_GOV",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100508276","phase-4-comparison-of-a-personalized-maintenance-therapy-with-the-standard-treatment-in-pemphigus-100508276","NCT05898308","Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","Comparison of a Personalized Maintenance Therapy Based on the Evolution of Anti-desmoglein Antibodies as Biomarkers of Pemphigus Subclinical Activity, With the Standard Treatment (Rituximab + Corticosteroids) in Pemphigus","RITUX4","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 80 years\n* Signed Informed Consent Form (or from the family in case of impossibility of patient's consent).\n* Confirmed newly diagnosed PV or PF, based on the presence of the following: histological features of acantholysis on skin or mucosal biopsy, and deposition of IgG, complement component 3, or both on the keratinocyte membrane detected by direct immunofluorescence on affected skin or mucosa\n* Presence of moderate-to-severely active disease, defined by an overall PDAI score\\> 1554\n* Patient able to receive the standard-of-care consisting of corticosteroids (prednisone 1 mg\u002Fkg\u002Fday PO) and rituximab\n* Patients must be vaccinated against Covid-19 before study entry. It is recommended that patients are vaccinated against influenza and Streptococcus pneumoniae and have their first injection (Prevenar 13) before study entry.\n* For women who are not postmenopausal (menopausal: ≥ 12 months of non-therapy-induced amenorrhoea) or surgically sterile (absence of ovaries and\u002For uterus + bilateral salphingectomy) and who do not plan on having children anymore: agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of \\\u003C1% per year, during the treatment period and for at least 12 months after the last dose of study treatment. They must have a negative result from a blood beta-HCG test within 1 week prior to randomization Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n\nBarrier methods must always be supplemented with the use of a spermicide.\n\n• For men: Surgical sterility or agreement to remain abstinent or use a condom during the treatment period and for at least 12 months after the last dose of study treatment and agreement to refrain from donating sperm during this same period.\n\nAbstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient.\n\nPeriodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n\n* Able to comply with the study protocol, in the investigator's judgment\n* Patient affiliated with, or beneficiary of a social security (national health insurance) plan\n\nExclusion Criteria:\n\n* Non-consenting patient or patient who cannot be followed regularly.\n* Diagnosis of paraneoplastic pemphigus or evidence of other non-PV or PF autoimmune blistering disease\n* Contraindication to rituximab marketed as 500 mg concentrate for solution for infusion\n* Contraindication to prednisone marketed as 20 mg, scored tablet pharmaceutical form\n* Contraindication to methylprednisolone marketed as 120 mg powder for injectable solution pharmaceutical form\n* Contraindication to paracetamol marketed as 10 mg\u002FmL solution for infusion pharmaceutical form\n* Contraindication to dexchlorpheniramine maleate marketed as 5 mg\u002F1mL injectable solution pharmaceutical form\n* Lack of peripheral venous access\n* Pregnant or lactating\n* Significant cardiovascular or pulmonary disease (including obstructive pulmonary disease)\n* Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude patient participation, including but not limited to nervous system, renal, hepatic, endocrine, malignant, or gastrointestinal disorders\n* Any concomitant condition that required treatment with oral or systemic corticosteroids within 12 weeks prior to randomization- excluding transitory treatments (such as a corticosteroid therapy prescribed for a few days for an acute infection), and chronic corticosteroid treatments with a prednisone \u002F prednisolone dose ≤20 mg\u002Fday, (these latter patients remain eligible for study entry)\n* Treatment with IV Ig, plasmapheresis, or other similar procedure within 8 weeks prior to randomization\n* Patients having received immunosuppressive treatment (such as cyclosporine, mycophenolate mofetil, azathioprine given at an effective dose for any other condition than Pemphigus, or any other treatment that might potentially be active on Pemphigus lesions (anti-TNF) within 4 weeks prior to baseline\n* Treatment with cyclophosphamide within 12 weeks prior to randomization\n* Patients with positive blood test for HIV\n* Inherited or acquired severe immune deficiency\n* Known active infection of any kind (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks prior to screening, or completion of oral anti-infectives within 2 weeks prior to randomization. Entry into this study may be reconsidered once the infection has fully resolved.\n* Patients with a currently treated cancer, including solid tumors, hematologic malignancies, and carcinoma (except basal cell of the skin and squamous cell carcinoma of the skin which can be easily cured with a standard excision )\n* Patients with a past history ( \\\u003C 5 years) of cancer, including solid tumors, hematologic malignancies, and carcinoma (except complete excision of basal cell of the skin and squamous cell carcinoma of the skin that have been excised and cured) NB: Patients whose cancer is cured and do not have anti-cancer treatment anymore must be referred to an oncologist before entry in the study\n* Currently active alcohol or drug abuse, or history of alcohol or drug abuse within 24 weeks prior to screening\n* Major surgery within 4 weeks prior to randomization, excluding diagnostic surgery\n* Treatment with rituximab or a B cell-targeted therapy (e.g., anti-CD20, anti-CD22, or anti-BLyS) within 12 months prior to randomization\n* Treatment with a live or attenuated vaccine within 28 days prior to randomization. It is recommended that a patient's vaccination record and the need for immunization prior to study entry be carefully investigated.\n* Major biological abnormality which in the investigator's judgment, would preclude patient participation,\n* Positive test results for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) serology at screening\n* Participation in another interventional clinical trial within 28 days prior to randomization and during the study\n* Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)","80 Years",{"count":85,"type":21},133,[87],"PHASE4","Pemphigus diseases are life-threatening chronic autoimmune blistering diseases characterized by split formation within the epidermis and surface-close epithelia accompanied by acantholysis. Autoantibodies (Abs) are mainly directed against two structural proteins of the epidermal\u002Fepithelial desmosome, desmoglein (Dsg) 1 and Dsg3. Two main pemphigus variants can be differentiated, pemphigus vulgaris (PV), and pemphigus foliaceus (PF). Diagnosis of PV and PF is based on the combination of the clinical picture, histological picture of acantholysis, direct immunofluorescence microscopy (DIF) of a perilesional biopsy and serology.\n\nThe present \"Ritux 4\" trial is the fourth academic study with the French study group on auto immune bullous skin diseases (Groupe Bulle) to assess the use of rituximab in auto immune bullous skin diseases, in particular pemphigus. The 3 previous trials have been published in outstanding Journals (N Engl J Med 2007, Science Transl Med 2013, The Lancet 2017 and 2020), and have led to the approval of rituximab in pemphigus by the FDA in 2018 and EMA in 2019. In addition, an industry-sponsored trial testing rituximab versus mycophenolate mofetil in pemphigus, that the investigators have largely contributed to design has been very recently accepted for publication in the N Engl J Med (2021).\n\nThe investigator hypothesize that a maintenance therapy using an infusion of 1g of rituximab at Month 6 in patients whose anti-Dsg Abs have not sufficiently decreased at Month 3 after the initial cycle of rituximab (persistence of anti-Dsg1 Abs\\> 20 UI\u002Fml and\u002For anti-Dsg3 Abs\\> 130 UI\u002Fml), and or had an initial PDAI score \\>45 ( first year of follow-up), and the re-treatment with 1g of rituximab of patients whose anti Dsg Abs re-increase during the evolution of pemphigus after the initial cycle of rituximab (anti-Dsg1 Abs\\> 20 IU\u002Fml, anti-Dsg3 Abs\\> 50 UI\u002Fml), could be effective in preventing the occurrence of relapses, thus avoiding to restart a CS treatment, and would provide benefit as compared with the current treatment strategy of retreating patients with 2 g of rituximab (1g at Day0 and Day14) combined with oral CS patients, once a clinical relapse occurs.",[90,31],"Pemphigus",[90,92,93,94],"Rituximab","Biomarkers","Personalized medicine","2026-02-17",{"date":97,"type":39},"2026-02-20",{"date":99,"type":39},"2024-12-04",{"date":101,"type":21},"2032-05-01",{"name":103,"class":104},"University Hospital, Rouen","OTHER",34,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":74},"100595493","a-skin-image-reference-tool-to-aid-healthcare-providers-diagnosis-100595493","NCT07033169","A Skin Image Reference Tool to Aid Healthcare Providers' Diagnosis","A Skin Image Reference Tool to Aid Healthcare Providers' Diagnosis of Commonly Encountered Dermatologic Diseases","Inclusion Criteria:\n\n* Patient must present to an Advocate Health dermatology clinic\n* Patient must have the ability and willingness to provide informed consent and comply with study procedures and visits\n* Participant dermatologists must have access to the required technology (e.g., smartphone with internet access) and be capable of using it for the required image capture\n\nExclusion Criteria:\n\n* Patients who are unable to comply with study procedures due to physical or mental health limitations (as assessed by study coordinator)\n* Pediatric, adolescent, and teen patients who present with dermatological conditions on their genitalia will not be included in the study (in support of patient privacy concerns).","10 Years",{"count":115,"type":21},400,"Consented patients will have three images taken of their dermatologic conditions within the Belle.ai software. These images will be uploaded and saved within the Belle software system where a single AI-generated differential list will be generated based on the three photos. All photos uploaded will be de-identified. The software will not have any unique identifiers of participants saved in the system. The photos will be named based on participant enrollment numbers or unique code numbers and no unique identifiers will be attached to the photos. There will be no data collection form necessary for this study",[31],[119,120,121],"artificial intelligence","skin diseases","dermatology","2025-10-22",{"date":124,"type":39},"2025-10-24",{"date":126,"type":39},"2025-09-15",{"date":128,"type":21},"2027-12",{"name":130,"class":104},"Wake Forest University Health Sciences",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100350911","collection-and-distribution-of-biospecimens-for-novel-research-uses-100350911","NCT03848962","Collection and Distribution of Biospecimens for Novel Research Uses","iSpecimen Network Protocol: Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research Uses","Inclusion Criteria:\n\n* Individual is developmentally aged 7 years old and above for RUO collections (only)\n* Individual meets requirements of a current request for research materials from iSpecimen\n* If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and\u002For the review of an updated medical history as provided by the participant\n* Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf.\n* Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf\n\nExclusion Criteria:\n\n* Subjects that do not meet the inclusion criteria outlined above.",true,"1 Month","89 Years",{"count":142,"type":21},10000,"iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations (\"institutions\") capable of providing researchers and educators (\"researchers\") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively \"research\").",[145,146,147,148,149,150,31,151],"Cancer","Healthy","Gastrointestinal Complication","Autoimmune Diseases","Infectious Disease","Women's Health: High-Risk Pregnancy","Blood Disease","2022-11-08",{"date":154,"type":39},"2022-11-09",{"date":156,"type":39},"2016-06-30",{"date":158,"type":21},"2026-12-31",{"name":160,"class":46},"iSpecimen Inc",2]